acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica
Company profile
Ticker
ACER
Exchange
Website
CEO
Christopher Schelling
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Opexa Therapeutics, Inc., PHARMAFRONTIERS CORP, PharmaFrontiers Corp., SPORTAN UNITED INDUSTRIES INC
SEC CIK
Corporate docs
IRS number
760333165
ACER stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
30 Nov 23
EFFECT
Notice of effectiveness
27 Nov 23
EFFECT
Notice of effectiveness
27 Nov 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Nov 23
Latest ownership filings
4
STEVE ASELAGE
20 Nov 23
4
JOHN MICHAEL DUNN
20 Nov 23
4
Donald Joseph
20 Nov 23
4
Chris Schelling
20 Nov 23
4
HARRY S PALMIN
20 Nov 23
4
Jefferson E Davis
20 Nov 23
SC 13D/A
TVM Life Science Ventures VI LP
30 Mar 23
4
Adrian W Quartel
16 Mar 23
4
Bernard H Paul
16 Mar 23
4
HARRY S PALMIN
16 Mar 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 594.66 k | 594.66 k | 594.66 k | 594.66 k | 594.66 k | 594.66 k |
Cash burn (monthly) | 319.59 k | 481.94 k | 4.29 mm | 2.29 mm | 4.79 mm | 3.10 mm |
Cash used (since last report) | 1.91 mm | 2.88 mm | 25.69 mm | 13.68 mm | 28.69 mm | 18.55 mm |
Cash remaining | -1.32 mm | -2.29 mm | -25.10 mm | -13.08 mm | -28.10 mm | -17.96 mm |
Runway (months of cash) | -4.1 | -4.8 | -5.8 | -5.7 | -5.9 | -5.8 |
Institutional ownership, Q2 2023
9.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 4 |
Closed positions | 6 |
Increased positions | 2 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 2.09 bn |
Total shares | 2.42 mm |
Total puts | 13.10 k |
Total calls | 1.70 k |
Total put/call ratio | 7.7 |
Largest owners | Shares | Value |
---|---|---|
Nantahala Capital Management | 1.14 mm | $1.05 bn |
Vanguard | 415.07 k | $383.27 mm |
Hudson Bay Capital Management | 274.30 k | $253.29 mm |
Anson Funds Management | 129.80 k | $119.85 mm |
Renaissance Technologies | 102.55 k | $95.00 k |
Geode Capital Management | 96.33 k | $88.95 mm |
BLK Blackrock | 76.77 k | $70.89 mm |
Hunter Associates Investment Management | 60.00 k | $55.00 k |
STT State Street | 53.04 k | $48.97 mm |
Two Sigma Securities | 24.61 k | $22.73 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Nov 23 | Dunn John Michael | Common Stock, $0.0001 par value per share | Sale back to company | Dispose D | No | No | 0 | 27,380 | 0.00 | 0 |
17 Nov 23 | Harry S Palmin | Common Stock, $0.0001 par value per share | Sale back to company | Dispose D | No | No | 0 | 125,000 | 0.00 | 0 |
17 Nov 23 | Schelling Chris | Common Stock, $0.0001 par value per share | Sale back to company | Dispose D | No | No | 0 | 2,712,529 | 0.00 | 0 |
17 Nov 23 | Jefferson E Davis | Common Stock, $0.0001 par value per share | Sale back to company | Dispose D | No | No | 0 | 71,645 | 0.00 | 0 |
17 Nov 23 | Joseph Donald | Common Stock, $0.0001 par value per share | Sale back to company | Dispose D | No | No | 0 | 14,285 | 0.00 | 0 |